Keywords: nuvelo, gains, rights, alfimeprase, amgen, gained, worldwide

Nuvelo gains rights to alfimeprase from Amgen

Article | 08 November 2004

Nuvelo has gained worldwide rights to develop and commercialize the novel thrombolytic agent, alfimeprase, from Amgen. The agent was originally ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amgen

Go to company listing